Subjects:
Free Research Articles
Topics:
diffuse large b-cell lymphoma

In Table 1 on page 1803 in the 19 October 2017 issue, there are errors in the row labeled “Indeterminate/missing.” Also, the footnote symbol “‡” should be added to the row heading “Total no. of lines of chemotherapy and ASCT received, %” and corresponding text should be added as is shown in the corrected footnote. The row's subheading “2” should read “2-3” and the subheading “3” should read “≥4.” The last row should be deleted. The corrected Table 1 is shown below.

Table 1.

Baseline patient characteristics

CharacteristicMDACC (n = 165)IA/MC (n = 82)LY.12 (CCTG) (n = 219)CORAL (LYSARC) (n = 170)Pooled (N = 636)
Median age, y (range) 56 (20-81) 60 (20-80) 54 (24-70) 54 (19-65) 55 (19-81) 
Male sex, % 64 62 61 69 64 
Primary diagnosis, %      
 DLBCL* 76 89 84 100 87 
 PMBCL 1 0 5 0 2 
 TFL 3 0 10 0 4 
 Indeterminate/missing 19 11 1 0 7 
ECOG PS, %      
 0-1 42 72 89 84 73 
 2-4 10 24 11 15 14 
 Missing 49 4 0 1 13 
Disease stage, %      
 I-II 18 20 33 32 27 
 III-IV 82 79 67 67 72 
 Missing 0 1 0 1 <1 
IPI risk classification, %†      
 Low risk 5 22 36 32 25 
 Low-intermediate risk 7 31 30 29 24 
 High-intermediate to high risk 23 48 35 34 33 
 Missing or incompletely assessed 65 0 0 5 18 
Refractory category, %      
 Primary refractory 0 24 51 28 28 
 Refractory to ≥ second-line therapy 90 51 21 46 50 
 Relapsed ≤12 mo post-ASCT 10 24 28 26 22 
Total no. of lines of chemotherapy and ASCT received, %‡      
 1 0 24 51 28 28 
 2-3 90 50 21 46 49 
 ≥4 0 1 0 0 <1 
CharacteristicMDACC (n = 165)IA/MC (n = 82)LY.12 (CCTG) (n = 219)CORAL (LYSARC) (n = 170)Pooled (N = 636)
Median age, y (range) 56 (20-81) 60 (20-80) 54 (24-70) 54 (19-65) 55 (19-81) 
Male sex, % 64 62 61 69 64 
Primary diagnosis, %      
 DLBCL* 76 89 84 100 87 
 PMBCL 1 0 5 0 2 
 TFL 3 0 10 0 4 
 Indeterminate/missing 19 11 1 0 7 
ECOG PS, %      
 0-1 42 72 89 84 73 
 2-4 10 24 11 15 14 
 Missing 49 4 0 1 13 
Disease stage, %      
 I-II 18 20 33 32 27 
 III-IV 82 79 67 67 72 
 Missing 0 1 0 1 <1 
IPI risk classification, %†      
 Low risk 5 22 36 32 25 
 Low-intermediate risk 7 31 30 29 24 
 High-intermediate to high risk 23 48 35 34 33 
 Missing or incompletely assessed 65 0 0 5 18 
Refractory category, %      
 Primary refractory 0 24 51 28 28 
 Refractory to ≥ second-line therapy 90 51 21 46 50 
 Relapsed ≤12 mo post-ASCT 10 24 28 26 22 
Total no. of lines of chemotherapy and ASCT received, %‡      
 1 0 24 51 28 28 
 2-3 90 50 21 46 49 
 ≥4 0 1 0 0 <1 

CCTG, Canadian Cancer Trials Group; LYSARC, Lymphoma Academic Research Organization.

*

In the CORAL (LYSARC) study, the disease subtype for 96 patients was not available; per the study inclusion criteria, patients were to have DLBCL.

†

IPI was determined at diagnosis for MDACC and IA/MC and at randomization for LY.12 and CORAL study patients; low risk, 0-1 point; low-intermediate risk, 2 points; high-intermediate to high risk, ≥3 points.

‡

Includes the 78% of patients who were refractory to chemotherapy and excludes those who relapsed post-ASCT.

View Large

On page 1806 in line 12 of the paragraph in the left column, the citation of reference 31 should be deleted. In line 16 of the same paragraph, the citation of reference 8 should be replaced with a citation of reference 37. In the reference list on page 1808, reference 37 should be added as follows:

37. Costa LJ, Maddocks K, Epperla N, et al. Diffuse large B-cell lymphoma with primary treatment failure: ultra-high risk features and benchmarking for experimental therapies. Am J Hematol. 2017;92(2):161-170.

The errors have been corrected in the online version, which now differs from the print version.

© 2018 by The American Society of Hematology
2018
Sign in via your Institution